Contineum Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 30, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item5. Other Information.
Trading Arrangements
From time to time, our officers (as defined in Rule16a-1(f) of the Exchange Act) and directors* mayenter into Rule10b5*-1 or non-Rule10b5-1 trading arrangements (as each such term is defined in Item408 of Regulation S-K). During thethree months ended* September 30, 2025*,none of our officers or directors adopted or terminated any such trading arrangements except as set forth below:
| Name | Action Taken | Type of | Nature of | Duration of | Aggregate Number |
|---|---|---|---|---|---|
| (Title) | (Date of Action) | Trading Arrangement | Trading Arrangement | Trading Arrangement | of Securities |
| Carmine Stengone (President and Chief Executive Officer) | Adoption ( September 23, 2025) | Rule 10b5-1 trading arrangement* | Sale | Until November 30, 2026, or such earlier date upon which all transactions are completed or expire without execution | Up to 231,925 shares |
| Peter Slover (Chief Financial Officer) | Adoption ( September 23, 2025) | Rule 10b5-1 trading arrangement* | Sale | Until November 18, 2026, or such earlier date upon which all transactions are completed or expire without execution | Up to 41,730 shares |
| Daniel Lorrain, Ph.D. (Chief Scientific Officer) | Adoption ( September 23, 2025) | Rule 10b5-1 trading arrangement* | Sale | Until November 30, 2026, or such earlier date upon which all transactions are completed or expire without execution | Up to 221,245 shares |
| Timothy Watkins, M.D., M.Sc. (Chief Medical Officer and Head of Development) | Adoption ( September 23, 2025) | Rule 10b5-1 trading arrangement* | Sale | Until December 27, 2026, or such earlier date upon which all transactions are completed or expire without execution | Up to 173,333 shares |
- Intended to satisfy the affirmative defense of Rule10b5-1(c)
22
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.